Researchers from China Pharmaceutical University and Nanjing First Hospital synthesized and optimized a novel series of thiohydantoin based compounds leading to the discovery of candidate [I] as the lead androgen receptor (AR) antagonist (IC50=1.46 µM).
Eikon Therapeutics Inc. has received IND clearance from the FDA to initiate phase I studies with IMP-1734, a highly selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor developed in partnership with Impact Therapeutics Inc.
Shanghai University of Traditional Chinese Medicine and Vestlandets Innovasjonsselskap AS (VIS) have disclosed bufalin derivatives acting as androgen receptor antagonists reported to be useful for the treatment of prostate cancer.
Essa Pharma Inc. has divulged androgen receptor antagonists reported to be useful for the treatment of metastatic castration-resistant prostate cancer.
Jiangsu Hengrui Medicine Co. Ltd., its subsidiary Shengdi Investment Management Holding Co. Ltd., and Hengrui Group are to invest ¥2.01 billion (US$301 million) to jointly set up an equity investment company targeting pharmaceutical and health care companies.
Jiangsu Hengrui Medicine Co. Ltd., its subsidiary Shengdi Investment Management Holding Co. Ltd., and Hengrui Group are to invest ¥2.01 billion (US$301 million) to jointly set up an equity investment company targeting pharmaceutical and health care companies.
Jiangsu Hengrui Medicine Co. Ltd. reported positive interim data from its phase III trial for SHR-3680, an androgen receptor antagonist, demonstrating that it reduced the risk of disease progression or death in metastatic hormone-sensitive prostate cancer patients with high-volume disease burden.
Jiangsu Hengrui Medicine Co. Ltd. reported positive interim data from its phase III trial for SHR-3680, an androgen receptor antagonist, demonstrating that it reduced the risk of disease progression or death in metastatic hormone-sensitive prostate cancer patients with high-volume disease burden.
